TECX TECTONIC THERAPEUTIC INC.

Tectonic Therapeutic to Participate in March Investor Conferences

Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.

TD Cowen 45th Annual Health Care Conference 
Date:March 5, 2025
Time:9:50 AM EST
Location:Boston, MA
Format:Corporate Presentation
Presenter:Alise Reicin, MD, President and Chief Executive Officer
Webcast: 



Leerink Partners Global Healthcare Conference
Date: March 11, 2025
Time:11:20 AM EDT
Location:Miami, FL
Format:Fireside Chat
Presenters:Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer
Webcast: 
  

Both live webcasts can also be accessed under “” on the Investors section of the Tectonic website at . Once these conferences have concluded, a replay of the two webcasts will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.

About Tectonic

 is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit and follow on .



Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
 

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
 
EN
20/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TECTONIC THERAPEUTIC INC.

 PRESS RELEASE

Tectonic Therapeutic Announces First Quarter 2025 Financial Results an...

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results...

 PRESS RELEASE

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of Ameri...

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Se...

 PRESS RELEASE

Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Soc...

Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that it will ma...

 PRESS RELEASE

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Finan...

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejec...

 PRESS RELEASE

Tectonic Therapeutic to Participate in March Investor Conferences

Tectonic Therapeutic to Participate in March Investor Conferences WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025. TD Cowen 45th Annual Health Care Conference Date:March 5, 2025Time:9:50 AM ESTLocation:Boston, MAFormat:Corporate PresentationPresenter:Ali...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch